Statement of Changes in Beneficial Ownership (4)
December 01 2020 - 05:01PM
Edgar (US Regulatory)
FORM 4
[ ]
Check this box if no longer subject to Section 16. Form 4 or Form 5
obligations may continue. See Instruction 1(b).
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
STATEMENT OF CHANGES IN BENEFICIAL
OWNERSHIP OF SECURITIES
|
OMB
APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response... 0.5 |
|
Filed pursuant to Section 16(a) of the
Securities Exchange Act of 1934 or Section 30(h) of the Investment
Company Act of 1940
|
|
1. Name
and Address of Reporting Person * Drexler Ryan
Charles |
2. Issuer Name and Ticker or Trading
Symbol MusclePharm Corp [ MSLP ] |
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)__X__
Director __X__
10% Owner
__X__ Officer (give title
below) _____ Other
(specify below)
CEO and President |
(Last)
(First)
(Middle)
C/O MUSCLEPHARM CORPORATION, 4500 PARK GRANADA, SUITE
202 |
3. Date of Earliest Transaction (MM/DD/YYYY)
11/29/2020
|
(Street)
CALABASAS, CA 91302
(City)
(State)
(Zip)
|
4. If Amendment, Date Original Filed
(MM/DD/YYYY)
|
6. Individual or Joint/Group Filing
(Check Applicable Line) _X _ Form filed by One Reporting Person
___ Form filed by More than One Reporting Person |
Table I - Non-Derivative Securities Acquired, Disposed of, or
Beneficially Owned
|
1.Title of Security
(Instr. 3) |
2. Trans. Date |
2A. Deemed Execution Date, if any |
3. Trans. Code
(Instr. 8) |
4. Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5) |
5. Amount of Securities Beneficially Owned Following
Reported Transaction(s)
(Instr. 3 and 4) |
6. Ownership Form: Direct (D) or Indirect (I)
(Instr. 4) |
7. Nature of Indirect Beneficial Ownership (Instr.
4) |
Code |
V |
Amount |
(A) or (D) |
Price |
Table II - Derivative Securities Beneficially Owned
(e.g., puts, calls, warrants, options, convertible
securities)
|
1. Title of Derivate Security
(Instr. 3) |
2. Conversion or Exercise Price of Derivative
Security |
3. Trans. Date |
3A. Deemed Execution Date, if any |
4. Trans. Code
(Instr. 8) |
5. Number of Derivative Securities Acquired (A) or
Disposed of (D)
(Instr. 3, 4 and 5) |
6. Date Exercisable and Expiration Date |
7. Title and Amount of Securities Underlying
Derivative Security
(Instr. 3 and 4) |
8. Price of Derivative Security
(Instr. 5) |
9. Number of derivative Securities Beneficially
Owned Following Reported Transaction(s) (Instr. 4) |
10. Ownership Form of Derivative Security: Direct
(D) or Indirect (I) (Instr. 4) |
11. Nature of Indirect Beneficial Ownership (Instr.
4) |
Code |
V |
(A) |
(D) |
Date Exercisable |
Expiration Date |
Title |
Amount or Number of Shares |
Convertible Promissory Note |
$0.23 |
11/29/2020 |
|
J |
|
$2871967 |
|
(1) |
7/1/2021 |
Common Stock |
12486813 |
$0.23 |
$2871967 |
D |
|
Explanation of
Responses: |
(1) |
On November 29, 2020, Mr.
Drexler entered into a convertible secured promissory note
agreement with a principal amount of $2,871,967 with the Company
(the "November 2020 Convertible Note"). Mr. Drexler may elect to
convert all or any portion of the convertible amount into shares of
the Company's common stock at any time for $0.23 per share at any
time. Both the principal and any accrued but unpaid interest under
the November 2020 Convertible Note will become due and payable on
July 1, 2021, unless earlier converted or repaid. |
Reporting
Owners
|
Reporting Owner Name / Address |
Relationships
|
Director |
10% Owner |
Officer |
Other |
Drexler Ryan Charles
C/O MUSCLEPHARM CORPORATION
4500 PARK GRANADA, SUITE 202
CALABASAS, CA 91302 |
X |
X |
CEO and President |
|
Signatures
|
/s/ Ryan Charles Drexler |
|
12/1/2020 |
**Signature of
Reporting Person |
Date |